Literature DB >> 27210308

Clinicopathological significance of lymphangiogenesis detected by immunohistochemistry using D2-40 monoclonal antibody in breast cancer.

Noriko Abe1, Tohru Ohtake, Katsuharu Saito, Kensuke Kumamoto, Takashi Sugino, Seiichi Takenoshita.   

Abstract

To elucidate the association between the lymphangiogenesis and clinicopathological factors including the survival in breast cancer, 91 Japanese patients with breast cancer were investigated. The lymphangiogenesis was evaluated by the count of lymph vessel density (LVD) with immunohistochemical method using D2-40 monoclonal antibody, a specific marker for lymphatic endothelial cells.D2-40-positive lymph vessels were detected in 87 of 91 cases, and were mainly distributed in the peritumoral lesions or around the tumor edge. There was a significant difference in disease-free survival (DFS) and overall survival (OS) between patients with high LVD and with low LVD (p=0.02, 0.01, respectively, log-rank test). In addition, LVD significantly correlated with the following clinicopathological factors: menopausal status (p<0.01), tumor size (p<0.01), lymph-node status (p=0.01) lymphatic vessel invasion (LVI) (p<0.01), blood vessel invasion (BVI) (p=0.03) and estrogen receptor status (ER) (p=0.02).Those data suggest that D2-40 monoclonal antibody is a useful marker for evaluating the LVD and its evaluation is helpful to predict the survival in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27210308      PMCID: PMC5131582          DOI: 10.5387/fms.2015-10

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  35 in total

Review 1.  Lymphangiogenesis in development and human disease.

Authors:  Kari Alitalo; Tuomas Tammela; Tatiana V Petrova
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

2.  Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours.

Authors:  Si Brask Sonne; Amy S Herlihy; Christina E Hoei-Hansen; John E Nielsen; Kristian Almstrup; Niels E Skakkebaek; Alexander Marks; Henrik Leffers; Ewa Rajpert-De Meyts
Journal:  Virchows Arch       Date:  2006-05-31       Impact factor: 4.064

3.  Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.

Authors:  T Niki; S Iba; M Tokunou; T Yamada; Y Matsuno; S Hirohashi
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

4.  Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa.

Authors:  T André; L Kotelevets; J C Vaillant; A M Coudray; L Weber; S Prévot; R Parc; C Gespach; E Chastre
Journal:  Int J Cancer       Date:  2000-04-15       Impact factor: 7.396

Review 5.  Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

Authors:  P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

6.  Lymphatic metastasis in the absence of functional intratumor lymphatics.

Authors:  Timothy P Padera; Ananth Kadambi; Emmanuelle di Tomaso; Carla Mouta Carreira; Edward B Brown; Yves Boucher; Noah C Choi; Douglas Mathisen; John Wain; Eugene J Mark; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2002-04-25       Impact factor: 47.728

7.  Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.

Authors:  Sebastian F Schoppmann; Guenther Bayer; Klaus Aumayr; Susanne Taucher; Silvana Geleff; Margaretha Rudas; Ernst Kubista; Hubert Hausmaninger; Hellmut Samonigg; Michael Gnant; Raimund Jakesz; Reinhard Horvat
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

8.  Lack of lymphangiogenesis during breast carcinogenesis.

Authors:  M M Vleugel; R Bos; P van der Groep; A E Greijer; A Shvarts; H V Stel; E van der Wall; P J van Diest
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

9.  Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site.

Authors:  Daisy W J van der Schaft; Patrick Pauwels; Sarah Hulsmans; Miriam Zimmermann; Lonneke V van de Poll-Franse; Arjan W Griffioen
Journal:  Cancer Lett       Date:  2007-04-17       Impact factor: 8.679

10.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.

Authors:  P Salven; A Lymboussaki; P Heikkilä; H Jääskela-Saari; B Enholm; K Aase; G von Euler; U Eriksson; K Alitalo; H Joensuu
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

View more
  5 in total

1.  The overexpression of PDGF-BB and its receptor is correlated with lymphatic metastasis in patients with non-small cell lung cancer.

Authors:  Ning Zhang; Huixian Hu; Yongqiang Fu; Fang He; Lili Wang; Shunhong Zhuang; Mingxing Ding
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

Review 2.  The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis.

Authors:  Song Zhang; Dong Zhang; Shanhong Yi; Mingfu Gong; Caibao Lu; Yuanqing Cai; Xuefeng Tang; Liguang Zou
Journal:  Oncotarget       Date:  2017-01-10

Review 3.  Nanomaterial-Based Drug Delivery System Targeting Lymph Nodes.

Authors:  Zesheng Cheng; Haiying Que; Li Chen; Qiu Sun; Xiawei Wei
Journal:  Pharmaceutics       Date:  2022-06-28       Impact factor: 6.525

4.  High lymphatic vessel density and presence of lymphovascular invasion both predict poor prognosis in breast cancer.

Authors:  Song Zhang; Dong Zhang; Mingfu Gong; Li Wen; Cuiwei Liao; Liguang Zou
Journal:  BMC Cancer       Date:  2017-05-17       Impact factor: 4.430

Review 5.  Lymphatic Endothelial Markers and Tumor Lymphangiogenesis Assessment in Human Breast Cancer.

Authors:  Jia-Mei Chen; Bo Luo; Ru Ma; Xi-Xi Luo; Yong-Shun Chen; Yan Li
Journal:  Diagnostics (Basel)       Date:  2021-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.